{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T03:10:13Z","timestamp":1793502613698,"version":"4.5.0"},"reference-count":91,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejinme.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ejim.2022.11.022","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T16:58:10Z","timestamp":1669049890000},"page":"18-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"special_numbering":"C","title":["Current approaches for the diagnosis and management of immune thrombocytopenia"],"prefix":"10.1016","volume":"108","author":[{"given":"Anat","family":"Gafter-Gvili","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2022.11.022_bib0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1111\/bjh.12480","article-title":"Cellular immune dysfunction in immune thrombocytopenia (ITP)","volume":"163","author":"McKenzie","year":"2013","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.ejim.2022.11.022_bib0002","doi-asserted-by":"crossref","DOI":"10.3390\/ph15070779","article-title":"Novel therapies to address unmet needs in ITP","volume":"15","author":"Mingot-Castellano","year":"2022","journal-title":"Pharmaceuticals"},{"issue":"6","key":"10.1016\/j.ejim.2022.11.022_bib0003","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2141.2009.07717.x","article-title":"Pathogenesis of chronic immune thrombocytopenia: increased platelet destruction and\/or decreased platelet production","volume":"146","author":"Nugent","year":"2009","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0004","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1080\/13696998.2019.1669329","article-title":"Primary immune thrombocytopenia in US clinical practice: incidence and healthcare burden in first 12 months following diagnosis","volume":"23","author":"Weycker","year":"2020","journal-title":"J Med Econ"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1600-0609.2009.01247.x","article-title":"The incidence of idiopathic thrombocytopenic purpura among adults: a population-based study and literature review","volume":"83","author":"Abrahamson","year":"2009","journal-title":"Eur J Haematol"},{"issue":"3","key":"10.1016\/j.ejim.2022.11.022_bib0006","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1002\/ajh.21616","article-title":"The incidence of immune thrombocytopenic purpura in children and adults: a critical review of published reports","volume":"85","author":"Terrell","year":"2010","journal-title":"Am J Hematol"},{"issue":"9","key":"10.1016\/j.ejim.2022.11.022_bib0007","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1002\/ajh.23262","article-title":"Prevalence of primary immune thrombocytopenia in Oklahoma","volume":"87","author":"Terrell","year":"2012","journal-title":"Am J Hematol"},{"issue":"Suppl 5","key":"10.1016\/j.ejim.2022.11.022_bib0008","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000492187","article-title":"Immune thrombocytopenia - current diagnostics and therapy: recommendations of a joint working group of DGHO, OGHO, SGH, GPOH, and DGTI","volume":"41","author":"Matzdorff","year":"2018","journal-title":"Oncol Res Treat"},{"issue":"3","key":"10.1016\/j.ejim.2022.11.022_bib0009","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1111\/jth.12813","article-title":"Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review","volume":"13","author":"Neunert","year":"2015","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0010","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1111\/bjh.12869","article-title":"Twenty-year mortality of adult patients with primary immune thrombocytopenia: a Danish population-based cohort study","volume":"166","author":"Frederiksen","year":"2014","journal-title":"Br J Haematol"},{"issue":"9","key":"10.1016\/j.ejim.2022.11.022_bib0011","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3324\/haematol.2016.146373","article-title":"Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome","volume":"101","author":"Grimaldi-Bensouda","year":"2016","journal-title":"Haematologica"},{"issue":"4","key":"10.1016\/j.ejim.2022.11.022_bib0012","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/bjh.13787","article-title":"Risk of arterial thrombotic and venous thromboembolic events in patients with primary chronic immune thrombocytopenia: a Scandinavian population-based cohort study","volume":"174","author":"Norgaard","year":"2016","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ejim.2022.11.022_bib0013","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.thromres.2014.10.012","article-title":"Risk of venous thromboembolism occurrence among adults with selected autoimmune diseases: a study among a U.S. cohort of commercial insurance enrollees","volume":"135","author":"Yusuf","year":"2015","journal-title":"Thromb Res"},{"issue":"23","key":"10.1016\/j.ejim.2022.11.022_bib0014","doi-asserted-by":"crossref","first-page":"3829","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert","year":"2019","journal-title":"Blood Adv"},{"issue":"22","key":"10.1016\/j.ejim.2022.11.022_bib0015","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1182\/bloodadvances.2019000812","article-title":"Updated international consensus report on the investigation and management of primary immune thrombocytopenia","volume":"3","author":"Provan","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.ejim.2022.11.022_bib0016","first-page":"1","article-title":"Idiopathic thrombocytopenia with iron deficiency anemia","volume":"6","author":"Ibrahim","year":"2013","journal-title":"Clin Med Insights Blood Disord"},{"issue":"7","key":"10.1016\/j.ejim.2022.11.022_bib0017","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1097\/00003246-197907000-00002","article-title":"Severe thrombocytopenia probably due to acute folic acid deficiency","volume":"7","author":"Mant","year":"1979","journal-title":"Crit Care Med"},{"issue":"1","key":"10.1016\/j.ejim.2022.11.022_bib0018","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/2249-4863.152276","article-title":"Vitamin B12 and vitamin d deficiencies: an unusual cause of Fever, severe hemolytic anemia and thrombocytopenia","volume":"4","author":"Mishra","year":"2015","journal-title":"J Family Med Prim Care"},{"issue":"4","key":"10.1016\/j.ejim.2022.11.022_bib0019","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1034\/j.1600-0609.2003.00033.x","article-title":"Pseudothrombocytopenia as a pitfall in the treatment of essential thrombocythemia","volume":"70","author":"Braester","year":"2003","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.ejim.2022.11.022_bib0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1365-2141.2009.07600.x","article-title":"Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology","volume":"145","author":"Levi","year":"2009","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ejim.2022.11.022_bib0021","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1182\/blood-2008-07-167155","article-title":"Effects of eradication of Helicobacter pylori infection in patients with immune thrombocytopenic purpura: a systematic review","volume":"113","author":"Stasi","year":"2009","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejim.2022.11.022_bib0022","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1182\/blood.V88.1.3.3","article-title":"Idiopathic thrombocytopenic purpura: a practice guideline developed by explicit methods for the American Society of Hematology","volume":"88","author":"George","year":"1996","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ejim.2022.11.022_bib0023","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1046\/j.1365-2141.2003.04131.x","article-title":"Guidelines for the investigation and management of idiopathic thrombocytopenic purpura in adults, children and in pregnancy","volume":"120","author":"British Committee for Standards in Haematology General Haematology Task","year":"2003","journal-title":"Br J Haematol"},{"issue":"1","key":"10.1016\/j.ejim.2022.11.022_bib0024","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1177\/107602960200800110","article-title":"The role of the bone marrow examination in the diagnosis of immune thrombocytopenic purpura: case series and literature review","volume":"8","author":"Jubelirer","year":"2002","journal-title":"Clin Appl Thromb Hemost"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0025","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/ejh.12041","article-title":"A blinded study of bone marrow examinations in patients with primary immune thrombocytopenia","volume":"90","author":"Mahabir","year":"2013","journal-title":"Eur J Haematol"},{"issue":"6","key":"10.1016\/j.ejim.2022.11.022_bib0026","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1046\/j.1365-2257.2000.00340.x","article-title":"The management of isolated thrombocytopenia in Chinese adults: does bone marrow examination have a role at presentation?","volume":"22","author":"Mak","year":"2000","journal-title":"Clin Lab Haematol"},{"issue":"6","key":"10.1016\/j.ejim.2022.11.022_bib0027","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.hoc.2009.08.003","article-title":"Thyroid disease in patients with immune thrombocytopenia","volume":"23","author":"Cheung","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"5","key":"10.1016\/j.ejim.2022.11.022_bib0028","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1111\/bjh.12318","article-title":"Thrombotic risk in patients with immune thrombocytopenia and its association with antiphospholipid antibodies","volume":"161","author":"Kim","year":"2013","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.ejim.2022.11.022_bib0029","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1111\/j.1365-2141.2008.07228.x","article-title":"Antiphospholipid antibodies in adults with immune thrombocytopenic purpura","volume":"142","author":"Pierrot-Deseilligny Despujol","year":"2008","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ejim.2022.11.022_bib0030","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1002\/ajh.24702","article-title":"Newly diagnosed immune thrombocytopenia adults: clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort","volume":"92","author":"Moulis","year":"2017","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ejim.2022.11.022_bib0031","first-page":"75","article-title":"Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases","volume":"29","author":"Arnal","year":"2002","journal-title":"J Rheumatol"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0032","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/ajh.23609","article-title":"Hydroxychloroquine is a good second-line treatment for adults with immune thrombocytopenia and positive antinuclear antibodies","volume":"89","author":"Khellaf","year":"2014","journal-title":"Am J Hematol"},{"issue":"1","key":"10.1016\/j.ejim.2022.11.022_bib0033","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1182\/asheducation-2018.1.561","article-title":"How do we diagnose immune thrombocytopenia in 2018?","volume":"2018","author":"Kelton","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"10.1016\/j.ejim.2022.11.022_bib0034","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/j.hoc.2009.09.003","article-title":"The immune thrombocytopenia syndrome: a disorder of diverse pathogenesis and clinical presentation","volume":"23","author":"Cines","year":"2009","journal-title":"Hematol Oncol Clin North Am"},{"issue":"11","key":"10.1016\/j.ejim.2022.11.022_bib0035","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2022.11.022_bib0036","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1182\/asheducation.V2012.1.306.3798320","article-title":"Pathogenesis in immune thrombocytopenia: new insights","volume":"2012","author":"Johnsen","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"9","key":"10.1016\/j.ejim.2022.11.022_bib0037","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1111\/jth.14227","article-title":"Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults","volume":"16","author":"Piel-Julian","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"10","key":"10.1016\/j.ejim.2022.11.022_bib0038","article-title":"High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"3","author":"Mithoowani","year":"2016","journal-title":"Lancet Haematol"},{"issue":"8","key":"10.1016\/j.ejim.2022.11.022_bib0039","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1111\/jth.15368","article-title":"Definition of a critical bleed in patients with immune thrombocytopenia: communication from the ISTH SSC Subcommittee on Platelet Immunology","volume":"19","author":"Sirotich","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0040","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1634\/stemcells.2008-0366","article-title":"Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist","volume":"27","author":"Erickson-Miller","year":"2009","journal-title":"Stem Cells"},{"issue":"4","key":"10.1016\/j.ejim.2022.11.022_bib0041","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1111\/j.1365-2141.2006.06339.x","article-title":"An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura","volume":"135","author":"Newland","year":"2006","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ejim.2022.11.022_bib0042","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima","year":"2019","journal-title":"Haematologica"},{"issue":"7","key":"10.1016\/j.ejim.2022.11.022_bib0043","article-title":"TPO receptor agonist for chronic idiopathic thrombocytopenic purpura","author":"Zeng","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"10.1016\/j.ejim.2022.11.022_bib0044","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter","year":"2013","journal-title":"Br J Haematol"},{"issue":"11","key":"10.1016\/j.ejim.2022.11.022_bib0045","doi-asserted-by":"crossref","first-page":"2807","DOI":"10.1111\/trf.12139","article-title":"Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists","volume":"53","author":"Ghadaki","year":"2013","journal-title":"Transfusion"},{"issue":"3","key":"10.1016\/j.ejim.2022.11.022_bib0046","doi-asserted-by":"crossref","first-page":"E40","DOI":"10.1002\/ajh.23900","article-title":"Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia","volume":"90","author":"Gonzalez-Lopez","year":"2015","journal-title":"Am J Hematol"},{"issue":"23","key":"10.1016\/j.ejim.2022.11.022_bib0047","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2017-04-748707","article-title":"Safety and efficacy of long-term treatment of chronic\/persistent ITP with eltrombopag: final results of the EXTEND study","volume":"130","author":"Wong","year":"2017","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0048","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1080\/09537104.2020.1745168","article-title":"Thrombopoietin receptor agonists for the treatment of primary immune thrombocytopenia: a meta-analysis and systematic review","volume":"32","author":"Birocchi","year":"2021","journal-title":"Platelets"},{"key":"10.1016\/j.ejim.2022.11.022_bib0049","series-title":"NPLATE\u00ae (romiplostim) for injection, for subcutaneous use [prescribing information]","year":"2018"},{"key":"10.1016\/j.ejim.2022.11.022_bib0050","series-title":"PROMACTA\u00ae (eltrombopag) tablets, for oral use; PROMACTA\u00ae (eltrombopag) for oral suspension [prescribing information]","year":"2018"},{"key":"10.1016\/j.ejim.2022.11.022_bib0051","series-title":"DOPTELET\u00ae (avatrombopag) tablets, for oral use [prescribing information]","year":"2019"},{"issue":"12","key":"10.1016\/j.ejim.2022.11.022_bib0052","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.medcli.2015.03.014","article-title":"Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: systematic review and meta-analysis of randomized controlled trials","volume":"145","author":"Catala-Lopez","year":"2015","journal-title":"Med Clin"},{"issue":"12","key":"10.1016\/j.ejim.2022.11.022_bib0053","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1007\/s00277-021-04669-8","article-title":"Targeted therapies for immune thrombocytopenic purpura: a meta-analysis of randomized controlled trials","volume":"100","author":"Cohen","year":"2021","journal-title":"Ann Hematol"},{"issue":"3","key":"10.1016\/j.ejim.2022.11.022_bib0054","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s12185-015-1837-6","article-title":"Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim","volume":"102","author":"Cines","year":"2015","journal-title":"Int J Hematol"},{"issue":"10","key":"10.1016\/j.ejim.2022.11.022_bib0055","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1182\/blood-2008-04-150078","article-title":"Safety and efficacy of long-term treatment with romiplostim in thrombocytopenic patients with chronic ITP","volume":"113","author":"Bussel","year":"2009","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ejim.2022.11.022_bib0056","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1007\/s00277-016-2682-2","article-title":"Changes in bone marrow morphology in adults receiving romiplostim for the treatment of thrombocytopenia associated with primary immune thrombocytopenia","volume":"95","author":"Janssens","year":"2016","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.ejim.2022.11.022_bib0057","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1002\/ajh.24011","article-title":"Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: data from the EXTEND study","volume":"90","author":"Brynes","year":"2015","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ejim.2022.11.022_bib0058","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/bjh.16775","article-title":"Practical guidance for the management of adults with immune thrombocytopenia during the COVID-19 pandemic","volume":"189","author":"Pavord","year":"2020","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ejim.2022.11.022_bib0059","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1159\/000082102","article-title":"The biology of CD20 and its potential as a target for mAb therapy","volume":"8","author":"Cragg","year":"2005","journal-title":"Curr Dir Autoimmun"},{"issue":"3","key":"10.1016\/j.ejim.2022.11.022_bib0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2141.2012.09169.x","article-title":"Rituximab before splenectomy in adults with primary idiopathic thrombocytopenic purpura: a meta-analysis","volume":"158","author":"Auger","year":"2012","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0061","doi-asserted-by":"crossref","first-page":"e75","DOI":"10.1016\/S2352-3026(15)00003-4","article-title":"Rituximab plus standard of care for treatment of primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"2","author":"Chugh","year":"2015","journal-title":"Lancet Haematol"},{"issue":"25","key":"10.1016\/j.ejim.2022.11.022_bib0062","doi-asserted-by":"crossref","first-page":"5989","DOI":"10.1182\/blood-2011-11-393975","article-title":"Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia","volume":"119","author":"Patel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2022.11.022_bib0063","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.ejca.2017.01.021","article-title":"Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis","volume":"76","author":"Vidal","year":"2017","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.ejim.2022.11.022_bib0064","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1600-0609.2010.01486.x","article-title":"Low-dose rituximab in adult patients with primary immune thrombocytopenia","volume":"85","author":"Zaja","year":"2010","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.ejim.2022.11.022_bib0065","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1002\/ajh.23272","article-title":"Long-term follow-up analysis after rituximab salvage therapy in adult patients with immune thrombocytopenia","volume":"87","author":"Zaja","year":"2012","journal-title":"Am J Hematol"},{"issue":"22","key":"10.1016\/j.ejim.2022.11.022_bib0066","doi-asserted-by":"crossref","first-page":"3228","DOI":"10.1182\/blood-2014-06-582346","article-title":"Safety and efficacy of rituximab in adult immune thrombocytopenia: results from a prospective registry including 248 patients","volume":"124","author":"Khellaf","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ejim.2022.11.022_bib0067","series-title":"MabThera (rituximab) [summary of product characteristics]","year":"2018"},{"issue":"12","key":"10.1016\/j.ejim.2022.11.022_bib0068","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1002\/ajh.25632","article-title":"Long-term safety and efficacy of rituximab in 248 adults with immune thrombocytopenia: results at 5 years from the French prospective registry ITP-ritux","volume":"94","author":"Deshayes","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"10.1016\/j.ejim.2022.11.022_bib0069","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1182\/blood-2013-04-494096","article-title":"The effect of rituximab on vaccine responses in patients with immune thrombocytopenia","volume":"122","author":"Nazi","year":"2013","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ejim.2022.11.022_bib0070","doi-asserted-by":"crossref","first-page":"7743","DOI":"10.1038\/s41598-022-11857-7","article-title":"Seroconversion to mRNA SARS-CoV-2 vaccines in patients with autoimmune cytopenias and bone marrow failures","volume":"12","author":"Fattizzo","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ejim.2022.11.022_bib0071","doi-asserted-by":"crossref","first-page":"715","DOI":"10.3324\/haematol.2021.279216","article-title":"Humoral serological response to the BNT162b2 vaccine is abrogated in lymphoma patients within the first 12 months following treatment with anti-CD2O antibodies","volume":"107","author":"Gurion","year":"2022","journal-title":"Haematologica"},{"issue":"1","key":"10.1016\/j.ejim.2022.11.022_bib0072","doi-asserted-by":"crossref","first-page":"9","DOI":"10.2217\/imt-2017-0097","article-title":"Fostamatinib for persistent\/chronic adult immune thrombocytopenia","volume":"10","author":"Newland","year":"2018","journal-title":"Immunotherapy"},{"key":"10.1016\/j.ejim.2022.11.022_bib0073","series-title":"TAVALISSE\u2122 (fostamatinib disodium hexahydrate) tablets, for oral use [prescribing information]","year":"2018"},{"issue":"7","key":"10.1016\/j.ejim.2022.11.022_bib0074","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/ajh.25125","article-title":"Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials","volume":"93","author":"Bussel","year":"2018","journal-title":"Am J Hematol"},{"issue":"5","key":"10.1016\/j.ejim.2022.11.022_bib0075","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ajh.25444","article-title":"Long-term fostamatinib treatment of adults with immune thrombocytopenia during the phase 3 clinical trial program","volume":"94","author":"Bussel","year":"2019","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.ejim.2022.11.022_bib0076","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1111\/bjh.16959","article-title":"Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia","volume":"190","author":"Boccia","year":"2020","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.ejim.2022.11.022_bib0077","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1161\/ATVBAHA.115.306883","article-title":"The novel oral syk inhibitor, Bl1002494, protects mice from arterial thrombosis and thromboinflammatory brain infarction","volume":"36","author":"van Eeuwijk","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.ejim.2022.11.022_bib0078","doi-asserted-by":"crossref","DOI":"10.1177\/20406207211010875","article-title":"Assessment of thrombotic risk during long-term treatment of immune thrombocytopenia with fostamatinib","volume":"12","author":"Cooper","year":"2021","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0079","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1111\/bjh.15090","article-title":"A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP","volume":"181","author":"Rodeghiero","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0080","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/bjh.13827","article-title":"Remission and platelet responses with romiplostim in primary immune thrombocytopenia: final results from a phase 2 study","volume":"172","author":"Newland","year":"2016","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.ejim.2022.11.022_bib0081","first-page":"1041","article-title":"The course of severe autoimmune thrombocytopenia in patients not undergoing splenectomy","volume":"91","author":"Sailer","year":"2006","journal-title":"Haematologica"},{"issue":"9","key":"10.1016\/j.ejim.2022.11.022_bib0082","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1182\/blood-2004-03-1168","article-title":"Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications","volume":"104","author":"Kojouri","year":"2004","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.ejim.2022.11.022_bib0083","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1182\/blood-2012-12-467068","article-title":"Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopenia","volume":"121","author":"Boyle","year":"2013","journal-title":"Blood"},{"issue":"48","key":"10.1016\/j.ejim.2022.11.022_bib0084","doi-asserted-by":"crossref","first-page":"e5098","DOI":"10.1097\/MD.0000000000005098","article-title":"Long-term complications of splenectomy in adult immune thrombocytopenia","volume":"95","author":"Thai","year":"2016","journal-title":"Medicine"},{"issue":"9","key":"10.1016\/j.ejim.2022.11.022_bib0085","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1007\/s00277-016-2738-3","article-title":"Long-term outcome following splenectomy for chronic and persistent immune thrombocytopenia (ITP) in adults and children : splenectomy in ITP","volume":"95","author":"Ahmed","year":"2016","journal-title":"Ann Hematol"},{"issue":"11","key":"10.1016\/j.ejim.2022.11.022_bib0086","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1080\/17474086.2021.1995347","article-title":"Immune thrombocytopenia","volume":"14","author":"Bussel","year":"2021","journal-title":"Expert Rev Hematol"},{"issue":"4","key":"10.1016\/j.ejim.2022.11.022_bib0087","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/bjh.13622","article-title":"Mycophenolate mofetil therapy for severe immune thrombocytopenia","volume":"171","author":"Taylor","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0088","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1365-2141.1990.tb02569.x","article-title":"Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases","volume":"74","author":"Quiquandon","year":"1990","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.ejim.2022.11.022_bib0089","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1182\/blood.V85.2.351.351","article-title":"Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura","volume":"85","author":"Reiner","year":"1995","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ejim.2022.11.022_bib0090","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1002\/ajh.22266","article-title":"Dapsone salvage therapy for adult patients with immune thrombocytopenia relapsed or refractory to steroid and rituximab","volume":"87","author":"Zaja","year":"2012","journal-title":"Am J Hematol"},{"issue":"8","key":"10.1016\/j.ejim.2022.11.022_bib0091","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/1076029615622002","article-title":"The effect of Danazol in primary immune thrombocytopenia: an analysis of a large cohort from a single center in China","volume":"22","author":"Liu","year":"2016","journal-title":"Clin Appl Thromb Hemost"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522004125?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0953620522004125?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T09:37:22Z","timestamp":1760607442000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0953620522004125"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":91,"alternative-id":["S0953620522004125"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2022.11.022","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Current approaches for the diagnosis and management of immune thrombocytopenia","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2022.11.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}